Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.

Sattar N, Gerstein HC, D'Alessio D, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, Nauck MA, Nissen SE, Zinman B, Zoungas S, Bartee A, Miller D, Nishiyama H, Qu Y, Weerakkody G, Wiese RJ, Pavo I, Nicholls SJ

Open source

DOI: 10.2337/dc26-0298
Published: 2026 Oct 1
Container: Diabetes care
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2337/dc26-0298,
  title = {Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.},
  author = {Sattar N and Gerstein HC and D'Alessio D and Bhatt DL and Buse JB and Del Prato S and Kahn SE and Lincoff AM and McGuire DK and Nauck MA and Nissen SE and Zinman B and Zoungas S and Bartee A and Miller D and Nishiyama H and Qu Y and Weerakkody G and Wiese RJ and Pavo I and Nicholls SJ},
  year = {2026},
  journal = {Diabetes care},
  doi = {10.2337/dc26-0298},
  url = {https://doi.org/10.2337/dc26-0298}
}

RIS

TY  - JOUR
TI  - Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
AU  - Sattar N
AU  - Gerstein HC
AU  - D'Alessio D
AU  - Bhatt DL
AU  - Buse JB
AU  - Del Prato S
AU  - Kahn SE
AU  - Lincoff AM
AU  - McGuire DK
AU  - Nauck MA
AU  - Nissen SE
AU  - Zinman B
AU  - Zoungas S
AU  - Bartee A
AU  - Miller D
AU  - Nishiyama H
AU  - Qu Y
AU  - Weerakkody G
AU  - Wiese RJ
AU  - Pavo I
AU  - Nicholls SJ
PY  - 2026
JO  - Diabetes care
DO  - 10.2337/dc26-0298
UR  - https://doi.org/10.2337/dc26-0298
ER  -

APA

N, S., HC, G., D, D., DL, B., JB, B., S, D. P., SE, K., AM, L., DK, M., MA, N., SE, N., B, Z., S, Z., A, B., D, M., H, N., Y, Q., G, W., RJ, W., I, P., & SJ, N. (2026). Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.. Diabetes care. https://doi.org/10.2337/dc26-0298

Source records

pubmed · retrieved 2026-09-25T22:20:31.778Z
europe-pmc · retrieved 2026-09-25T22:20:31.794Z